PRAX Stock Analysis: Praxis Precision Medicines | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 7.063m USD | 12M Return: 43.9% | US74006W2070 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 137M
Qual. Beats: 2
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Praxis Precision Medicines (PRAX) is a U.S.-based, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing precision therapies for central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance. The company operates two technology platforms-Cerebrum for orally bioavailable small molecules and Solidus for antisense oligonucleotide (ASO) discovery-and is advancing a pipeline led by ulixacaltamide (NDA-stage for essential tremor), relutrigine (NDA-stage for SCN2A/SCN8A DEEs; Phase 3 for broad DEEs), vormatrigine (Phase 3 focal epilepsy), and Elsunersen (Phase 3 SCN2A-DEE), alongside earlier preclinical candidates including PRAX-020, PRAX-080, PRAX-090, and PRAX-100.
As is typical for clinical-stage biopharmas, Praxis relies on capital markets and partnership milestones rather than product revenue, supporting discovery, clinical development, and NDA-enabling activities. The company maintains external collaborations with RogCon, Ionis Pharmaceuticals, and an unnamed iontophoretic transdermal patch developer for ulixacaltamide delivery. The GICS sub-industry classification is Biotechnology, and the stock trades on NASDAQ as a mid-cap (~$8.25B USD market cap), having gone public in October 2020.
- Ulixacaltamide NDA decision for essential tremor approaches
- Phase 3 relutrigine DEE and vormatrigine epilepsy data readouts
- Cash runway and capital raises fund late-stage CNS pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 20.19 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -305.7m > Net Income -339.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.1m) vs 12m ago 35.65% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 1.71%; Δ -1.71% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.52 (Total Current Assets 771.9m - Total Current Liabilities 49.1m) / Total Assets 1.39b |
| B: -0.95 (Retained Earnings -1.32b / Total Assets 1.39b) |
| C: -0.37 (EBIT TTM -339.1m / Avg Total Assets 921.5m) |
| D: 27.34 (Book Value of Equity 1.34b / Total Liabilities 49.1m) |
| Altman-Z'' = 26.55 = AAA |
As of October 28, 2026, the stock is trading at USD 267.59 with a total of 382,295 shares traded. Over the past week, the price has changed by +1.17%, over one month by -6.32%, over three months by -15.27% and over the past year by +43.91%.
Current recommended Stop Loss: 251.30 (which is 6.1% or 1.2 ATR below the current price).
Praxis Precision Medicines has received a consensus analysts rating of 4.52. Therefore, it is recommended to buy PRAX.
- StrongBuy: 15
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 650 | 142.9% |
P/S = 144.694
P/B = 6.8867
Revenue TTM = 0.0 USD
EBIT TTM = -339.1m USD
EBITDA TTM = -339.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.09m USD (from shortTermDebt, last quarter)
Debt = 1.09m USD (from shortLongTermDebtTotal, last quarter) (leases 1.09m already included)
Net Debt = -757.5m USD (calculated: Debt 1.09m - CCE 758.6m)
Enterprise Value = 6.31b USD (7.06b + Debt 1.09m - CCE 758.6m)
Interest Coverage Ratio = unknown (Ebit TTM -339.1m / Interest Expense TTM 0.0)
EV/FCF = -20.61x (Enterprise Value 6.31b / FCF TTM -306.0m)
FCF Yield = -4.85% (FCF TTM -306.0m / Enterprise Value 6.31b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 140k) / Revenue TTM)
Tobins Q-Ratio = 4.54 (Enterprise Value 6.31b / Total Assets 1.39b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.09m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -267.9m (EBIT -339.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.73 (Total Current Assets 771.9m / Total Current Liabilities 49.1m)
Debt / Equity = 0.00 (Debt 1.09m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = 2.23 (negative EBITDA) (Net Debt -757.5m / EBITDA -339.0m)
Debt / FCF = 2.48 (negative FCF - burning cash) (Net Debt -757.5m / FCF TTM -306.0m)
Total Stockholder Equity = 993.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.80% (Net Income -339.1m / Total Assets 1.39b)
RoE = -34.15% (Net Income TTM -339.1m / Total Stockholder Equity 993.2m)
RoCE = -34.15% (EBIT -339.1m / Capital Employed (Equity 993.2m + L.T.Debt 0.0))
RoIC = -19.96% (negative operating profit) (NOPAT -267.9m / Invested Capital 1.34b)
WACC = 12.54% (E(7.06b)/V(7.06b) * Re(12.54%) + D(1.09m)/V(7.06b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.15 | Cagr: 38.92%
[DCF] Fair Price = unknown (Cash Flow -306.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.65 | # QB: 2
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-3.63 | Chg30d=-0.08% | Revisions=+42% | Analysts=19
EPS current Year (2026-12-31): EPS=-14.02 | Chg30d=-0.64% | Revisions=+74% | GrowthEPS=-4.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-9.50 | Chg30d=-2.24% | Revisions=+0% | GrowthEPS=+32.2% | GrowthRev=+41442.6%
[Analyst] Revisions Ratio: +59% (up=28, down=6)